A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT05630183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Study identification
- NCT ID
- NCT05630183
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2023 (Actual)
- Primary completion
- Jan 5, 2026 (Actual)
- Completion
- Jan 5, 2026 (Actual)
- Last update posted
- Jun 11, 2026
2023 – 2026
United States locations
- U.S. sites
- 36
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth | Scottsdale | Arizona | 85258 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| USC Norris Oncology | Newport Beach | California | 92663 | — |
| UCLA Health - Santa Monica Cancer Care | Santa Monica | California | 90404 | — |
| Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| Florida Cancer Specialist South | Fort Myers | Florida | 33901 | — |
| Cancer Care Centers of Brevard | Palm Bay | Florida | 32909 | — |
| Florida Cancer Specialist North | St. Petersburg | Florida | 22705 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| Maryland Oncology Hematology | Columbia | Maryland | 21044 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Rogel Cancer Center, University of Michigan Medicine | Ann Arbor | Michigan | 48109 | — |
| Minnesota Oncology | Minneapolis | Minnesota | 55404 | — |
| Nebraska Medicine-Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II* | Las Vegas | Nevada | 89144 | — |
| John Theurer Cancer Center at Hackensack | Hackensack | New Jersey | 07601 | — |
| Atlantic Health Systems, Morristown | Morristown | New Jersey | 07960 | — |
| Overlook Medical Center | Summit | New Jersey | 07901 | — |
| Weill Cornell Medicine-New York Presbyterian Hospital | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Medicine Sandra and Edward Meyer Cancer Center | New York | New York | 10065 | — |
| Icahn School of Medicine at Mount Sinai Tisch Cancer Institute | New York | New York | 10128 | — |
| Oncology Hematology Care - Eastgate | Cincinnati | Ohio | 45245 | — |
| Sarah Cannon Research Institute at Tennessee Oncology | Cincinnati | Ohio | 45245 | — |
| Lifespan | Providence | Rhode Island | 02903 | — |
| Sarah Cannon Research Institute at Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology | Carrollton | Texas | 75010 | — |
| Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75247 | — |
| TxO - Denison Cancer Center | Denison | Texas | 75020 | — |
| The Center for Cancer & Blood Disorders: Fort Worth | Fort Worth | Texas | 76104 | — |
| Northeast Texas Cancer & Research Institute | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates - Brock Cancer Center | Norfolk | Virginia | 23502 | — |
| Shenandoah Oncology | Winchester | Virginia | 22601 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05630183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05630183 live on ClinicalTrials.gov.